Purpose The role of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in the treatment
of type 1 diabetes mellitus (T1DM), including efficacy and safety evidence, is reviewed …

Glucagon-like peptide-1 (GLP-1) has been evaluated for use in the treatment of type 2
diabetes mellitus (T2DM) due to its role in glucose regulation. Four GLP-1 receptor agonists …

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are commonly used in combination
with insulin to manage type 2 diabetes mellitus, and four agents are currently approved for …

Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly being
used for the treatment of type 2 diabetes mellitus, but consideration of benefits and potential …

Glucagon-like peptide-1 receptor analogues/agonists (GLP-1RAs) are well established as
effective adjuncts to lifestyle modification in the treatment of type 2 diabetes (T2D) as …

More than 26 million people in the United States have type 2 diabetes mellitus (T2D). Many
treatment options exist, but achieving long‐term glycemic control in patients with T2D …

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are injectable
glucose-lowering medications approved for the treatment of adult patients with type 2 …

Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) act by increasing insulin
secretion, decreasing glucagon secretion, slowing gastric emptying, and increasing satiety …

For patients with type 2 diabetes mellitus, glucagon-like peptide-1 receptor agonists (GLP-
1RAs) generally exert robust glucose-lowering effects that are at least as effective as insulin …

Over the last decade, the discovery of glucagon-like peptide 1 receptor agonists (GLP-1
RAs) has increased the treatment options for patients with type 2 diabetes mellitus (T2DM) …